Is the pharmaceutical siting framework just reverse-engineered to justify choosing Edo State?

The analysis does favour the Edo corridor, and readers should know that. But the eight criteria are industry-standard, and any site can be scored against them independently, including scoring Edo down. A reverse-engineered case hides the chosen site's weaknesses; this one publishes them, including a gas-supply vulnerability that cost the country over 1.9 million dollars during a five-day plant shutdown. A framework you can turn against the author's own preferred site is the opposite of motivated reasoning.

Is gas-supply risk disqualifying for a pharmaceutical plant that cannot tolerate power interruptions?

Gas-supply risk is real, and a power event in pharma can mean a lost batch and a compliance investigation. But no Nigerian site is risk-free, so the test is whether the risk is mitigable or structural. A corridor with multiple independent power plants and an established gas base is mitigable through redundant generation, contracted supply and on-site fuel reserve. A site with no reliable power base is structural and cannot be engineered around. The honest position states the risk and its mitigation rather than claiming there is none.

Why trust a location case when the site is not yet secured?

The land is identified, not secured, and securing it is an open milestone. But the siting logic does not depend on a single parcel: the case is for the corridor and the criteria, and it holds regardless of which plot is acquired. A shared-infrastructure park matters here because the value is in the power, water and effluent solution engineered for the site, which travels with the project rather than with one title deed. Judge the reasoning on the criteria and the land on the milestone tracker.

Is Edo State actually pharma-ready or just a general industrial location?

Edo's visible momentum is largely general manufacturing and electronics, and pharma is a more demanding tenant. The industrial fundamentals of power, water, logistics and technical labour are substantially shared, which makes the corridor a credible starting point. But pharma adds pharmaceutical-grade water, compliant effluent for chemical synthesis, and GMP-classified environments, which a general park does not solve. Closing that gap is what a life-sciences-specific park exists to do. The fundamentals are necessary but not sufficient.

Couldn't any competing state park recite the same siting criteria?

Reciting the criteria is easy and every park does it. Satisfying the first four, power, gas, water and effluent, with verifiable existing infrastructure rather than a masterplan is where most sites fail, and it is why so many announced parks stall at feasibility. The differentiator is not a better checklist but a site that can already evidence the fundamentals, paired with shared infrastructure that closes any remaining gap. A competitor can copy the criteria but not a corridor where a single plant already contributes around a tenth of the national grid.

Where should you locate a pharmaceutical manufacturing plant in Nigeria?

The right site is the one that solves power, water and effluent before you arrive, not the one offered on the most generous terms. In Nigerian pharmaceutical manufacturing, siting is not a real estate decision made after the plant is designed, it’s the decision that determines whether the plant is economic to operate at all. Below is the eight criterion framework we use to assess a site, and why the gas-rich industrial corridor of the South South scores well against it.
Author: Theodora Ogharanduku, CEO - Knectiv. Last reviewed: Aug 18, 2026

The siting mistake that stalls projects

Most Nigerian industrial siting decisions are made politically rather than commercially. A parcel of land is allocated, a state announces a park, and the technical question - can this specific site deliver uninterrupted clean power, pharmaceutical-grade water, compliant effluent discharge and port logistics at an economic cost? - is deferred until the feasibility study.

That deferral is why so many announced parks never progress past feasibility. The study eventually asks the question the site selection should have answered first, and the numbers do not close. By then the political commitment is public and the project quietly stalls rather than relocating.

The discipline is straightforward and rarely applied: choose the site against the technical criteria, then negotiate the terms - not the reverse.

A free parcel in the wrong place is the most expensive land in Nigeria.

The eight criteria that decide a pharmaceutical site

1. Power - quality and continuity, not just availability

GMP manufacturing needs uninterrupted, stable, clean power. Interruption is not merely lost output; in pharmaceutical production a power event can compromise a batch, invalidate environmental monitoring and trigger a deviation investigation. The question is never “is there grid supply?” but “what is the realistic availability, what is the cost per kWh delivered, and what is the backup architecture?”

2. Gas supply security

Where reliable industrial power comes from gas fired independent power plants, your power risk is gas supply risk. Proximity to gas infrastructure is an advantage but supply security, not just proximity, is what to underwrite. See the honest caveat below.

3. Water - volume and quality

Pharmaceutical manufacturing needs large volumes of water that can be treated to purified water and Water for Injection standard. Source availability, baseline quality and treatment cost vary enormously by site, and treatment capex is a direct function of how poor the raw source is.

4. Effluent discharge feasibility

Particularly decisive for API synthesis. The site must permit compliant treatment and discharge to environmental standard. Sites that cannot support this are disqualified regardless of every other advantage - and this is the criterion most often discovered too late.

5. Logistics - ports, roads, inputs

Distance and reliable road access to seaports govern both imported input costs and export viability. For a project whose economics depend on regional or international sales, this isn’t a convenience factor; it’s a margin factor.

6. Technical labour and academic proximity

Because Nigeria’s pool of API process chemistry, GMP qualification and validation expertise is thin, proximity to universities and technical institutions matters more here than in most industries - both for recruitment and for the knowledge transfer partnerships this sector depends on.

7. Land tenure, title security and expansion room

A site with clean, verifiable title and a clear path to a registrable long term lease or ownership structure is a different risk proposition from one carrying disputed or informally held land. Title disputes surface at the worst possible moment - after capital is committed - and a DFI will underwrite title risk as carefully as it underwrites the engineering. Room to expand on the same site also matters: a facility that succeeds will want to add capacity, and relocating a second phase because the original plot was too small is an avoidable cost.

8. State-level incentives and institutional speed

Free zone status, tax and customs treatment matter but so does how quickly a state actually processes approvals, permits and land documentation. A generous incentive regime administered slowly is worth less than a modest one administered fast. Assess the institution, not just the offer.

How to use this: score candidate sites against all eight before negotiating on any of them. A site that fails criterion 4 or scores badly on 1 and 2 should be eliminated no matter how attractive criterion 8 looks.

Why the South-South gas corridor scores well

Edo State performs strongly against several of the criteria above, on public evidence rather than assertion.

Power and gas - the state is an established gas-to-power hub. Azura-Edo alone has been reported to contribute around 10% of electricity supply to the national grid, with roughly six multinationals generating power from natural gas in the state (Edo State Government). The Ossiomo independent power plant at Ologbo supplies industrial users, and the state has more recently launched a 100MW power plant alongside an LNG facility explicitly aimed at industrial growth (Federal Ministry of Information).

Logistics - industrial development around Benin City benefits from road connections to the seaports at Sapele and Warri (Pulse), and Benin sits on the principal road route between Nigeria’s northern, western, eastern and southern regions (Edo State Investment Promotion Office).

Technical labour - the University of Benin and the state’s technical colleges provide a graduate pipeline, with on-site innovation centres supporting research partnerships (Pulse) directly relevant to the knowledge transfer dependency that defines this sector.

Incentives and institutions - Edo operates a free trade area with tax and customs incentives (Pulse) and has established an ease of doing business committee and investment promotion office to compress approval timelines (Vanguard).

The honest caveat - gas supply security

No site in Nigeria is without risk, and it would be dishonest to present one. Gas-fired industrial power carries gas supply risk. When the Ossiomo plant was shut down for five days, the disruption was reported to have cost the country over $1.9 million, with sabotage, theft and vandalism cited among the sector’s challenges (Edo State Government).

For a pharmaceutical facility, that is a material risk requiring explicit mitigation: redundant generation, contracted supply security, on-site fuel reserve and a power architecture designed so that no single supply failure can compromise a batch. A siting analysis that does not model this has not been done properly.

We publish this because any competent analyst will find it, and a project that hides its site risks is a project you should not fund.

What this means for your feasibility study

Criteria 1 through 4 - power, gas, water and effluent - are the ones that most often break a Nigerian pharmaceutical business case, and they are also the ones a single manufacturer must solve alone and pay for alone. They are the reason Genesis Science Park exists as shared infrastructure - designed intentionally so those four criteria are answered at park level before a tenant designs a plant.

Land for the park has been identified in Edo State, with engineering led by an experienced engineering partner. The technical criteria has already been fulfilled so manufacturers don’t have to, leaving the feasibility study to focus on what really matters - the commercial and regulatory business case.

→ Express your interest and download the technical prospectus.

For manufacturers that are undertaking a feasibility study, or are operational and expanding.

FAQs

You’ve obviously already chosen Edo. Isn’t this “framework” just reverse-engineered to justify a decision you’d already made?

Fair challenge, and worth testing directly: score Edo against the eight criteria yourself and see where it holds up and where it doesn’t - the honest caveat on gas supply security is on this page precisely because we’re not hiding the parts that don’t flatter the choice. The framework existed before the site did; Edo scores well against it on public evidence, not the reverse. If a stronger site existed against these criteria, the discipline described on this page is to move to it, not defend the one already chosen.

You admit the gas supply can fail. For pharmaceutical manufacturing, where a power event can destroy a batch, isn’t that disqualifying?

It would be disqualifying if the plan was to rely on a single gas-fired line with no redundancy - which is exactly why it isn’t the plan. The honest caveat exists so the risk is engineered around rather than assumed away: redundant generation, contracted supply security and on-site fuel reserve are the explicit mitigations this page names, not optional extras. No site in Nigeria is risk-free; the question is whether a site’s risks are named and mitigated, or undisclosed and discovered later. This one is named.

Why should I trust a location case when your own site isn’t even secured? You may not get the land.

You’re right that land has been identified but not yet secured, and we’d rather you hear that from us than discover it later. What this page argues doesn’t depend on Genesis Science Park’s specific plot succeeding - the eight-criteria framework and the case for the South-South corridor stand on their own evidence. Land security is a project-execution milestone we track and report on transparently, not a claim we’re asking you to take on faith.

Most of Edo’s industrial momentum looks like electronics and general manufacturing. Pharma is different. Are you borrowing an industrial park story that doesn’t fit?

Pharma is different, which is why this page scores the site against pharma-specific criteria rather than general industrial ones - effluent discharge feasibility and Water-for-Injection-grade water access don’t appear on most industrial park checklists, and they’re criteria 3 and 4 here. Edo’s general industrial momentum is relevant context, not the argument itself; the argument is that gas-fired power, port logistics, a university pipeline and institutional speed independently satisfy the specific criteria a pharmaceutical facility needs, whatever else is being built nearby.

“Location is king” and these eight criteria are things any state park could recite. What is actually differentiated here?

Most parks can recite criteria; few score a specific site against them with named sources and an honest caveat attached. The differentiation isn’t the list of eight, it’s doing the work the list implies before the plant is designed - and being willing to publish the risk that doesn’t flatter the pitch, like the gas supply caveat above. That discipline, not the framework itself, is what most announced parks skip.